Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.6%

Tyra Biosciences, Inc. (NASDAQ:TYRAGet Free Report) dropped 4.6% during mid-day trading on Friday . The stock traded as low as $18.23 and last traded at $18.23. Approximately 62,194 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 129,166 shares. The stock had previously closed at $19.10.

Wall Street Analyst Weigh In

TYRA has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a report on Friday, May 10th. Finally, Oppenheimer reissued an “outperform” rating and issued a $28.00 price objective (up from $25.00) on shares of Tyra Biosciences in a research report on Monday, May 13th.

Check Out Our Latest Report on Tyra Biosciences

Tyra Biosciences Price Performance

The business’s 50-day simple moving average is $16.93 and its two-hundred day simple moving average is $15.36.

Tyra Biosciences (NASDAQ:TYRAGet Free Report) last posted its quarterly earnings data on Tuesday, March 19th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). As a group, equities research analysts predict that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, COO Daniel Bensen sold 2,050 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $20.00, for a total transaction of $41,000.00. Following the transaction, the chief operating officer now owns 442,836 shares of the company’s stock, valued at $8,856,720. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 4,728 shares of company stock valued at $94,716. Insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in Tyra Biosciences by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 41,870 shares of the company’s stock worth $577,000 after acquiring an additional 1,074 shares during the last quarter. Simplex Trading LLC lifted its holdings in Tyra Biosciences by 198.1% in the third quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock worth $27,000 after acquiring an additional 1,335 shares during the last quarter. Corton Capital Inc. bought a new position in Tyra Biosciences in the third quarter worth about $152,000. Wellington Management Group LLP lifted its holdings in Tyra Biosciences by 18.5% in the third quarter. Wellington Management Group LLP now owns 94,112 shares of the company’s stock worth $1,296,000 after acquiring an additional 14,676 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Tyra Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock worth $132,000 after acquiring an additional 2,417 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Further Reading

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.